Daniel Ollendorf News Today

The groundbreaking treatment is one of six gene therapies cleared since 2017 that have transformed the outlook for disorders once considered hopeless — and also renewed questions about how the health care system can afford such breathtakingly expensive medicines.

Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing ...

Newly launched U.S. drugs head toward record-high prices in 2022

By Deena Beasley (Reuters) - Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their ...

Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing power even as Congress moves to cut the $500 billion-plus annual bill

The pharmaceutical industry is coming under fire again for their pricing as they are launching new medicines at record prices this year.

When Biogen cut the price of its Alzheimer's drug in half, it exposed the arbitrary nature of drug pricing.

The drugmaker and insurer's outcomes-based agreement offers rebates for ALK-positive NSCLC patients who discontinue Alunbrig after three months.